Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. MarketScreener Strategies
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 10/18 10:59:45 am
667.2 DKK   +1.40%
10:52aNOVO NORDISK A/S : Share repurchase programme - Form 6-K
PU
09:34aNOVO NORDISK A/S : – Share repurchase programme
AQ
06:29aNOVO NORDISK : Gets a Buy rating from Barclays
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S : No turn-around in sight

09/16/2021 | 02:40am EDT
long trade
Live
Entry price : 636.2DKK | Target : 680.6DKK | Stop-loss : 607DKK | Potential : 6.98%
The timing appears opportune to go long in shares of Novo Nordisk A/S as we anticipate another pick-up in the underlying trend.
Investors have an opportunity to buy the stock and target the DKK 680.6.
Novo Nordisk A/S : Novo Nordisk A/S : No turn-around in sight
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses
  • The company benefits from high valuations in earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart
Subsector Other Pharmaceuticals
1st jan.Capitalization (M$)Investor Rating
NOVO NORDISK A/S54.22%234 792
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657
MERCK & CO., INC.-4.24%198 283
ABBVIE INC.2.03%193 205
ASTRAZENECA PLC20.08%187 492
NOVARTIS AG-8.03%186 330
BRISTOL-MYERS SQUIBB COMPAN..-5.92%129 683
SANOFI6.53%122 086
More Results

© MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2021 138 B 21 460 M 21 460 M
Net income 2021 46 461 M 7 250 M 7 250 M
Net cash 2021 6 424 M 1 002 M 1 002 M
P/E ratio 2021 33,0x
Yield 2021 1,49%
Capitalization 1 527 B 238 B 238 B
EV / Sales 2021 11,1x
EV / Sales 2022 10,0x
Nbr of Employees 45 971
Free-Float 69,8%
Upcoming event on NOVO NORDISK A/S
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 667,20 DKK
Average target price 611,52 DKK
Spread / Average Target -8,35%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology